Pedro Dorado
Pedro Dorado
Dirección de correo verificada de unex.es
Título
Citado por
Citado por
Año
Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype
Ü Yasar, C Forslund‐Bergengren, G Tybring, P Dorado, A LLerena, ...
Clinical Pharmacology & Therapeutics 71 (1), 89-98, 2002
2442002
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
P Dorado, R Berecz, MJ Norberto, Ü Yasar, ML Dahl, A LLerena
European journal of clinical pharmacology 59 (3), 221-225, 2003
1252003
QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations
A Llerena, R Berecz, P Dorado, A de la Rubia
Journal of psychopharmacology 18 (2), 189-193, 2004
922004
Lower frequency of CYP2C9* 2 in Mexican-Americans compared to Spaniards
A Llerena, P Dorado, F O'kirwan, R Jepson, J Licinio, ML Wong
The pharmacogenomics journal 4 (6), 403-406, 2004
872004
Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use
P Dorado, MC Cáceres, E Pozo-Guisado, ML Wong, J Licinio, A Llerena
Biotechniques 39 (4S), S571-S574, 2005
852005
CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
A Llerena, P Dorado, R Ramírez, I González, M Alvarez, EM Peñas-Lledó, ...
The Pharmacogenomics Journal 12 (2), 176-183, 2012
842012
Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
A LLerena, P Dorado, EM Peñas-Lledó
Future Medicine Ltd 10 (1), 17-28, 2009
842009
Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers
I González, EM Peñas-Lledó, B Pérez, P Dorado, M Álvarez, A LLerena
Future Medicine Ltd 9 (7), 833-840, 2008
822008
Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
A LLerena, P Dorado, R Berecz, AP González, EM Peñas-LLedó
European journal of clinical pharmacology 59 (12), 869-873, 2004
792004
QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients
A LLerena, R Berecz, A de la Rubia, P Dorado
Journal of psychopharmacology 16 (4), 361-364, 2002
702002
CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits
P Dorado, EM Peas-LLed, A LLerena
Pharmacogenomics 8 (11), 2007
682007
Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
R Berecz, A de la Rubia, P Dorado, P Fernández-Salguero, ML Dahl, ...
European journal of clinical pharmacology 59 (1), 45-50, 2003
662003
Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients
A LLerena, P Dorado, R Berecz, A González, MJ Norberto, A de la Rubia, ...
Journal of Chromatography B 783 (1), 25-31, 2003
642003
The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions
R Berecz, P Dorado, ADL Rubia, MC Caceres, I Degrell, A LLerena
Current drug targets 5 (6), 573-579, 2004
622004
CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
P Dorado, MG Sosa-Macias, EM Peñas-Lledó, RE Alanis-Bañuelos, ...
The pharmacogenomics journal 11 (2), 108-112, 2011
592011
Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions
A LLerena, R Berecz, P Dorado, CS de la Garza, MJ Norberto, M Cáceres, ...
Journal of Chromatography B 783 (1), 213-219, 2003
572003
High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders
EM Peñas-Lledó, P Dorado, Z Agüera, M Gratacós, X Estivill, ...
Mol Psychiatry 16 (7), 691-2, 2011
562011
Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers
EM Peñas-LLedó, P Dorado, R Pacheco, I González, A LLerena
Pharmacogenomics 10 (7), 1111-1120, 2009
562009
Low frequency of CYP2D6 poor metabolizers among schizophrenia patients
A Llerena, P Dorado, EM Peñas-Lledó, MC Cáceres, A De la Rubia
The pharmacogenomics journal 7 (6), 408-410, 2007
542007
Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes
A LLerena, R Berecz, A de la Rubia, P Fernández-Salguero, P Dorado
Therapeutic drug monitoring 23 (6), 616-620, 2001
542001
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20